The development of widespread depigmentation is a rare post transplant phenomenon observed in patients undergoing hematopoietic SCT (HSCT). We report our experience with a pediatric patient who developed total leukoderma with leukotrichia following HSCT and review the literature on previously reported pediatric cases.
A 15-year-old boy with a history of X-linked SCID was presented to our dermatology clinic for evaluation. He had undergone HSCT at the age of 8 months with haploidentical T-cell depleted donor cells from his mother without pre transplant conditioning. His immediate post-transplant course was notable for grade three acute GVHD initially occurring on day þ 17, which was responsive to prednisone. Upon resolution of acute GVHD, his mother noted rapid and progressive whitening of his skin and hair. He had a history of numerous sunburns, even with minimal sun exposure. He subsequently developed chronic GVHD of the skin (localized sclerotic type), lungs, liver and the gastrointestinal tract. On presentation to our clinic, medications included IVIG once every three weeks, mycophenolate mofetil 750 mg twice daily, prednisone 20 mg daily, trimethoprim-sulfamethoxazole thrice weekly and voriconazole 200 mg twice daily. Immunosuppressive medications were employed for management of chronic visceral GVHD. He had never received treatment for skin depigmentation. There was no family history of vitiligo or other disease of melanocytes or melanin biosynthesis.
On full cutaneous examination, generalized depigmentation of the skin and hair was noted (Figures 1a and b) . His irises were pale slate gray in color. Multiple gritty papules consistent with actinic keratosis, as well as two ulcerated lesions consistent with squamous cell carcinoma in situ, were noted. 1 Histopathology of skin from the thigh revealed complete absence of melanocytes and melanin in the epidermal basal layer (Figure 1c ). FontanaMasson stain for melanin and immunohistochemistry for MART-1 Figure 1 . Total leukoderma of the face, torso, neck and back with total leukotrichia of the hair in a child following HSCT (a, b). Skin biopsy of the child's thigh, stained with hematoxylin and eosin stain, 40x magnification, demonstrating complete absence of melanocytes in the basal layer of the epidermis (c). MART-1 immunofluorescence stain, 40x magnification, of the same skin lesion confirming complete absence of melanocytes as evidenced by a complete lack of immunostaining (d).
and S100 were negative (Figure 1d) . Photographs of the patient prior to HSCT revealed brown hair and Fitzpatrick skin type III pigmentation, similar to his parents.
Widespread depigmentation is a rare occurrence following HSCT (see Table 1 ). [2] [3] [4] [5] [6] [7] Only two additional pediatric cases of total leukoderma and leukotrichia have been reported in the literature to date. 3, 4 Both cases were of male children 14 years of age at HSCT in whom depigmentation occurred 3-5 months after transplant. As a result of his young age at transplant, our case is unique as depigmentation occurred during infancy. His pigmentation disorder went unrecognized for many years leading to the prolonged use of voriconazole, a known photosensitizing and photocarcinogenic agent. 8 There have been no reports of nonmelanoma skin cancer in the setting of depigmentation other than in this patient. 1 The cause of depigmentation after HSCT is unknown. Although there are cases associated with a donor history of vitiligo, suggesting adoptive transfer of autoimmunity, there is no such association in most cases. 9 In all three cases of children with total leukoderma and leukotrichia (including ours), there is a consistent history of cutaneous acute and/or chronic GVHD in HSCT recipients with vitiligo. We speculate that acute injury to keratinocytes and melanocytes in cutaneous GVHD may lead to exposure of melanocyte specific Ag to donor cytotoxic T cells via epitope spreading. Recognition of melanocyte Ag by donor T cells as foreign may then elicit a persistent immune response against host melanocytes. The occurrence of other autoimmune conditions after HSCT supports this hypothesis. 10 Interestingly, the report of other children with SCID who developed localized vitiligo after HSTC (not as generalized nor as persistent as in our patient) raises the question of an association or predisposition between the disease and this post-transplant complication that warrants further exploration. 7 No successful treatments for reversal of post transplant total leukoderma have been reported in the literature to date. Therapeutic options for vitiligo such as topical steroids, topical calcineurin inhibitors and ultraviolet phototherapy may be considerations for such patients, though none of these have been rigorously evaluated for depigmentation in this population. Treatment was not considered in our patient due to the widespread and longstanding nature of his leukoderma.
In young HSCT recipients, light skin and/or hair coloring should be evaluated carefully so as to avoid the assumption of inherent skin type. If depigmentation is noted in post-transplant patients, especially in the setting of chronic cutaneous GVHD, history of radiation exposure, sustained immunosuppression, or treatment with photosensitizing medications such as voriconazole; 7 particular attention must be given to counseling regarding sun protection and screening for the development of skin cancer. We advocate annual skin examinations specifically by a dermatologist if such identifiable risk factors are present.
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